GPCR
Structure Therapeutics Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-40/100
Last price
27.35
▼ 0.24 (0.89%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
27.70
Prev close
27.59
Day high
27.85
Day low
26.69
Volume
1.42M
Market cap
$1.96B
P/E (TTM)
—
52W range
25.59 – 94.90
Day trading desk
Gap from prior close
+0.40%
Prior close 27.59
VWAP
27.35
-0.02% from price
Relative volume
2.47×
Unusually busy
Session range
13.98%
26.32 – 30.00
Position in range
28%
Near session low
ATR (14D)
1.80
6.57% of price
Prior day high
28.20
PDH
Prior day low
26.41
PDL
Bid / ask spread
—
Quote not published
Session volume
2.34M
Avg 947.12K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-15.97%
-17.9%
1M
-41.97%
-43.1%
3M
-49.95%
-54.5%
6M
-49.76%
-67.9%
YTD
-60.50%
-74.8%
1Y
+0.70%
-15.7%
3Y
-45.52%
-127.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
16 more panels on GPCR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.22M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 1, 26 | LIN XICHEN Officer |
CONVERSION | 17.82K | $6.06K | Direct |
| Aug 18, 26 | LIN XICHEN Officer |
CONVERSION | 11.82K | $4.02K | Direct |
| Aug 6, 26 | BERRIOS JOHN JOSEPH Officer |
STOCK | 140.77K | $0 | Direct |
| Aug 4, 26 | LIN XICHEN Officer |
CONVERSION | 11.82K | $4.02K | Direct |
| Jul 14, 26 | LIN XICHEN Officer |
CONVERSION | 23.63K | $1.20M | Direct |
| Jun 25, 26 | LIN XICHEN Officer |
CONVERSION | 23.63K | $8.04K | Direct |
| Apr 15, 26 | LANG MATTHEW Chief Operating Officer |
STOCK | 184.61K | $0 | Direct |
| Mar 19, 26 | STEVENS RAYMOND C Chief Executive Officer |
STOCK | 260.22K | $0 | Direct |
| Mar 19, 26 | HALL ASHLEY Officer |
STOCK | 47.71K | $0 | Direct |
| Mar 19, 26 | MA YINGLI Chief Technology Officer |
STOCK | 32.53K | $0 | Direct |
| Mar 19, 26 | LIN XICHEN Officer |
STOCK | 43.37K | $0 | Direct |
| Mar 19, 26 | YOON JUN Chief Financial Officer |
STOCK | 104.08K | $0 | Direct |
| Mar 19, 26 | COLL CRESPO BLAS Officer |
STOCK | 75.90K | $0 | Direct |
| Jul 1, 25 | STEVENS RAYMOND C Chief Executive Officer |
STOCK | 89.70K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BERRIOS JOHN JOSEPH |
Officer | 140.77K | Stock Award(Grant) |
COLL CRESPO BLAS |
Officer | 280.88K | Stock Award(Grant) |
HALL ASHLEY |
Officer | 155.19K | Stock Award(Grant) |
LANG MATTHEW |
Chief Operating Officer | 184.61K | Stock Award(Grant) |
LIN XICHEN |
Officer | 228.96K | Conversion of Exercise of derivative security |
MA YINGLI |
Chief Technology Officer | 139.92K | Stock Award(Grant) |
STEVENS RAYMOND C |
Chief Executive Officer | 2.96M | Stock Award(Grant) |
YOON JUN |
Chief Financial Officer | 2.96M | Stock Award(Grant) |
Fundamentals
Market cap$1.96B
Enterprise value$622.45M
Revenue (TTM)—
Gross profit—
EBITDA$-265.79M
Net income$-214.84M
EPS (TTM)$-3.02
Free cash flow$-119.06M
Total cash$1.34B
Total debt$6.23M
Book value / share$19.02
Shares outstanding71.31M
Float55.46M
Short % of float12.68%
Dividend yield0.00%
Beta (5Y)-1.37
Valuation & profitability ratios
Trailing P/E—
Forward P/E-13.00
PEG ratio—
Price / sales—
Price / book1.44
EV / revenue—
EV / EBITDA-2.34
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-20.21%
Return on assets-14.95%
Debt / equity0.46
Current ratio20.75
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $225.25M | $108.81M | $70.10M | $36.19M | +107.0% |
| Selling, general & admin | $61.55M | $49.41M | $32.67M | $16.37M | +24.6% |
| Total operating expense | $186.81M | $158.23M | $102.78M | $52.56M | +18.1% |
| Operating income | -$186.81M | -$158.23M | -$102.78M | -$52.56M | -18.1% |
| Net interest income | $35.87M | $36.01M | $13.39M | $1.26M | -0.4% |
| Pre-tax income | -$140.69M | -$122.22M | -$89.38M | -$51.30M | -15.1% |
| Tax provision | $515.00K | $310.00K | $236.00K | $17.00K | +66.1% |
| Net income | -$141.20M | -$122.53M | -$89.62M | -$51.32M | -15.2% |
| Net income to common | -$141.20M | -$122.53M | -$89.62M | -$52.84M | -15.2% |
| Basic EPS | -1.99 | -2.14 | -2.43 | -1.38 | +6.8% |
| Diluted EPS | -1.99 | -2.14 | -2.43 | -1.38 | +6.8% |
| EBIT | -$186.81M | -$158.23M | -$102.78M | -$52.56M | -18.1% |
| EBITDA | -$185.48M | -$157.24M | -$102.48M | -$52.28M | -18.0% |
| Basic shares | 70.84M | 57.29M | 36.73M | 38.24M | +23.7% |
| Diluted shares | 70.84M | 57.29M | 36.73M | 38.24M | +23.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $799.62M | $169.51M | $129.79M | $26.09M | +371.7% |
| Cash & short-term investments | $1.45B | $883.52M | $467.32M | $90.84M | +63.7% |
| Total current assets | $1.57B | $891.21M | $473.61M | $93.09M | +76.2% |
| Property, plant & equipment | $12.90M | $7.01M | $8.36M | $1.29M | +83.9% |
| Total assets | $1.58B | $903.33M | $482.02M | $97.84M | +75.3% |
| Total current liabilities | $63.28M | $36.02M | $24.74M | $13.01M | +75.7% |
| Total debt | $6.49M | $3.86M | $5.45M | $260.00K | +68.0% |
| Total liabilities | $67.54M | $38.49M | $29.05M | $212.99M | +75.5% |
| Retained earnings | -$470.30M | -$329.10M | -$206.57M | -$116.95M | -42.9% |
| Shareholder equity | $1.52B | $864.84M | $452.97M | -$115.14M | +75.3% |
| Working capital | $1.51B | $855.19M | $448.87M | $80.08M | +76.2% |
| Net tangible assets | $1.52B | $864.84M | $452.97M | -$115.14M | +75.3% |
| Shares issued | 212.51M | 171.86M | 139.22M | 114.73M | +23.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$141.20M | -$122.53M | -$89.62M | -$51.32M | -15.2% |
| Depreciation & amortisation | $1.33M | $992.00K | $295.00K | $277.00K | +34.4% |
| Stock-based compensation | $28.99M | $18.79M | $8.19M | $2.51M | +54.3% |
| Change in working capital | -$88.04M | $2.96M | $6.97M | $2.97M | -3,070.3% |
| Operating cash flow | -$222.20M | -$116.64M | -$79.49M | -$46.12M | -90.5% |
| Capital expenditure | -$3.61M | -$1.29M | -$2.17M | -$155.00K | -180.2% |
| Investing cash flow | $89.80M | -$358.91M | -$268.34M | -$62.11M | +125.0% |
| Financing cash flow | $762.52M | $515.26M | $451.53M | $29.01M | +48.0% |
| Free cash flow | -$225.81M | -$117.93M | -$81.66M | -$46.27M | -91.5% |
| End cash position | $799.62M | $169.51M | $129.79M | $26.09M | +371.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $100.06M | $66.51M | $68.69M | $58.99M | $54.71M | +50.4% |
| Selling, general & admin | $18.57M | $22.87M | $17.57M | $14.80M | $15.74M | -18.8% |
| Total operating expense | $118.63M | $89.38M | -$13.74M | $73.79M | $70.45M | +32.7% |
| Operating income | -$118.63M | -$89.38M | $13.74M | -$73.79M | -$70.45M | -32.7% |
| Net interest income | $12.71M | $13.60M | $9.19M | $8.18M | $8.93M | -6.6% |
| Pre-tax income | -$105.92M | -$75.78M | $33.17M | -$65.60M | -$61.52M | -39.8% |
| Tax provision | $234.00K | $190.00K | $170.00K | $108.00K | $139.00K | +23.2% |
| Net income | -$106.16M | -$75.97M | $33.00M | -$65.71M | -$61.66M | -39.7% |
| Net income to common | -$106.16M | -$75.97M | $33.00M | -$65.71M | -$61.66M | -39.7% |
| Basic EPS | -1.47 | -1.05 | 0.47 | -1.11 | -1.07 | -40.0% |
| Diluted EPS | -1.47 | -1.05 | 0.47 | -1.11 | -1.07 | -40.0% |
| EBIT | -$118.63M | -$89.38M | $13.74M | -$73.79M | -$70.45M | -32.7% |
| EBITDA | -$118.08M | -$88.80M | $14.15M | -$73.43M | -$70.16M | -33.0% |
| Basic shares | 72.65M | 72.44M | 70.84M | 58.49M | 57.57M | +0.3% |
| Diluted shares | 72.65M | 72.44M | 70.84M | 58.49M | 57.57M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $272.64M | $316.17M | $799.62M | $102.91M | $147.02M | -13.8% |
| Cash & short-term investments | $1.34B | $1.46B | $1.45B | $799.04M | $786.50M | -7.9% |
| Total current assets | $1.37B | $1.49B | $1.57B | $814.02M | $799.30M | -8.0% |
| Property, plant & equipment | $12.39M | $11.97M | $12.90M | $11.54M | $10.94M | +3.5% |
| Total assets | $1.43B | $1.51B | $1.58B | $832.16M | $816.44M | -5.5% |
| Total current liabilities | $66.11M | $56.98M | $63.28M | $57.53M | $39.03M | +16.0% |
| Total debt | $6.23M | $5.79M | $6.49M | $7.09M | $7.68M | +7.5% |
| Total liabilities | $71.01M | $61.03M | $67.54M | $62.14M | $44.36M | +16.4% |
| Retained earnings | -$652.43M | -$546.27M | -$470.30M | -$503.30M | -$437.59M | -19.4% |
| Shareholder equity | $1.35B | $1.45B | $1.52B | $770.02M | $772.08M | -6.4% |
| Working capital | $1.31B | $1.43B | $1.51B | $756.50M | $760.26M | -8.9% |
| Net tangible assets | $1.35B | $1.45B | $1.52B | $770.02M | $772.08M | -6.4% |
| Shares issued | 213.21M | 213.21M | 212.51M | 182.03M | 172.70M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$106.16M | -$75.97M | $33.00M | -$65.71M | -$61.66M | — | -39.7% |
| Depreciation & amortisation | $551.00K | $576.00K | $412.00K | $356.00K | $291.00K | — | -4.3% |
| Stock-based compensation | $12.63M | $11.64M | $8.07M | $7.50M | $7.51M | — | +8.5% |
| Change in working capital | -$24.51M | $81.58M | -$93.83M | $9.51M | $3.08M | — | -130.0% |
| Operating cash flow | -$120.11M | $15.23M | -$64.42M | -$51.00M | -$54.56M | — | -888.5% |
| Capital expenditure | — | -$1.18M | -$1.50M | -$1.57M | -$232.00K | -$314.00K | — |
| Investing cash flow | $74.50M | -$496.95M | $56.14M | -$49.32M | $48.94M | — | +115.0% |
| Financing cash flow | $2.08M | -$1.74M | $704.99M | $56.20M | $517.00K | — | +219.7% |
| Free cash flow | -$120.07M | $14.05M | -$65.91M | -$52.57M | -$54.79M | — | -954.5% |
| End cash position | $272.64M | $316.17M | $799.62M | $102.91M | $147.02M | — | -13.8% |
Options analytics
Put / call volume
1.20
Put-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
25.00
-9.0% from spot
ATM implied vol
0.4%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
194
Contracts, this expiry
Put volume
233
Contracts, this expiry
Heaviest call OI
105.00
8 contracts
Heaviest put OI
25.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.38 | -0.49 | -28.3% |
| Mar 2026 | -0.31 | -0.35 | -12.9% |
| Dec 2025 | -0.37 | 0.20 | +154.2% |
| Sep 2025 | -0.37 | -0.37 | -0.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.24 | 10 | $50.00M | 0.0% |
| Next quarter | -0.49 | 10 | $0 | 0.0% |
| Current year | -1.62 | 11 | $41.67M | 0.0% |
| Next year | -2.19 | 9 | $45.45K | -99.9% |
Analyst targets & ownership
Mean target$105.78
High target$145.00
Low target$70.00
Implied upside286.84%
Analyst count15
ConsensusSTRONG BUY
Strong buy / Buy4 / 11
Hold1
Sell / Strong sell0 / 0
Held by insiders3.11%
Held by institutions97.70%
Institutions holding269
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
31.86
-14.18% from price
SMA 20
34.74
-20.93% from price
SMA 50
43.85
-37.36% from price
SMA 100
44.53
-38.60% from price
SMA 200
53.19
-48.35% from price
EMA 12
31.92
-14.33% from price
EMA 26
36.44
-24.95% from price
EMA 50
40.65
-32.73% from price
RSI (14)
16.5
Oversold
MACD (12,26,9)
-4.52
Hist -0.53
ATR (14)
1.80
6.54% of price
Realised vol 30D
63.7%
Annualised
Bollinger upper
42.86
20, 2σ
Bollinger lower
26.62
20, 2σ
50 / 200 cross
Death
43.85 vs 53.19
Trend bias
Below 200
-48.35%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.98
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
63.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-70.7%
Peak to trough
Max drawdown 5Y
-81.0%
Peak to trough
ATR 14
1.80
6.54% of price
Beta (reported)
-1.37
5Y monthly, from filing
Short interest
Shares short
6.61M
Prior 6.08M
Change vs prior
+8.6%
Shorts adding
% of float
12.68%
Elevated
% of shares out
9.26%
Against total outstanding
Days to cover
6.6
Crowded exit
Float
55.46M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 7, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jun 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 27, 26 | Canaccord Genuity | INITIATED | — | Buy |
| Mar 16, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 27, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jan 22, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jan 20, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Dec 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 12, 25 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-08
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-23
Corporate Changes & Voting Matters
8-K · 2026-04-15
Corporate Changes & Voting Matters
8-K · 2026-03-16
Periodic Financial Reports
10-K · 2026-02-26
Headlines
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
Zacks · 7d ago
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
Zacks · 14d ago
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
24/7 Wall St. · 15d ago
Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus
Simply Wall St. · 15d ago
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
Stocktwits · 15d ago
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
Zacks · 20d ago
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
Zacks · 20d ago
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Zacks · 23d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.